WXIBF News and Press, Wuxi Biologics Cayman Inc From 01/21/25

2025-01-21 17:18:58 ET Summary My rating upgrade for WuXi Biologics to a Buy has taken into consideration its latest corporate move and business disclosures. The sale of its European manufacturing facility will throw up margin improvement and capital allocation opportunities for W...

2025-01-06 11:24:08 ET More on Merck Merck: A Low-Hanging Fruit To Pick Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time Merck: Buy Opportunity Backed By Growth Brand prescription drugs to rise an average 4.5% in 2025 ...